KFDA to brace for expediting evaluation process of new biopharmaceuticals

Published: 2004-05-13 07:00:00

Updated: 2004-05-13 07:00:00

Despite Korean pharmaceutical firms's efforts to accelerate their R&D studies of new biopharmaceuticals, there are growing concerns that the insufficient number of eligible assessment specialists might become one of the major roadblocks for timely development of breakthrough biopharmaceuticals, a...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK